Algernon Pharmaceuticals Inc (OTCMKTS:BTHCF) CEO Christoper Moreau sat down with Proactive's Steve Darling at the 12th annual LD Micro Conference in Bel Air, California. The Vancouver, British Columbia-based clinical stage pharmaceutical development company is advancing its lead compounds for non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease and idiopathic pulmonary fibrosis.
Algernon Pharmaceuticals finding new uses for safe, older drugs
Quick facts: Algernon Pharmaceuticals Inc.
Price: 0.26 CAD
Market Cap: $23.41 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE